[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100302988":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":22,"centralContacts":27,"locations":35,"responsibleParty":54,"collaborators":10,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":10,"eligibilityCriteria":62,"healthyVolunteers":59,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":10,"studyType":69,"phases":10,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":38,"whyStopped":10,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Chongqing Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Primary aldosteronism",null,"screened, confirmed and subtyped according to the guidelines.",[13],"Other: no intervention",{"label":15,"type":10,"description":16,"interventionNames":17},"Essential hypertension","screened for PA and excluded the diagnosis of PA as well as other secondary hypertesion",[13],[19],{"type":6,"name":20,"description":20,"armGroupLabels":21,"otherNames":10},"no intervention",[15,9],[23],{"name":24,"affiliation":25,"role":26},"Qifu Li, phD","First Affiliated Hospital of Chongqing Medical University","STUDY_CHAIR",[28,32],{"name":24,"role":29,"phone":30,"phoneExt":10,"email":31},"CONTACT","+86 023-89011552","liqifu@yeah.net",{"name":33,"role":29,"phone":30,"phoneExt":10,"email":34},"Shumin Yang, phD","443068494@qq.com",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Qifu Li","RECRUITING","Chongqing","Chongqing Municipality","400016","China","CN",{"type":45,"coordinates":46},"Point",[47,48],106.55771,29.56026,{"lat":48,"lon":47},[51],{"name":52,"role":29,"phone":53,"phoneExt":10,"email":31},"Qifu Li, PhD","+86 23 89011552",{"type":55,"investigatorFullName":37,"investigatorTitle":56,"investigatorAffiliation":25,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Director of endocrinology","100302988","chongqing-primary-aldosteronism-study-100302988",false,"NCT03224312","Chongqing Primary Aldosteronism Study","Inclusion Criteria:\n\n1. hypertensive patients who completed ARR screening and necessary further tests;\n2. Voluntary to sign the informed consent.\n\nExclusion Criteria:\n\n1. patients with severe cardiac, hepatic or renal dysfunction;\n2. suspicious or confirmed other types of secondary hypertension, including Cushing's syndrome, pheochromocytoma and renal artery stenosis et al.","ALL","18 Years","80 Years",{"count":67,"type":68},1500,"ESTIMATED","OBSERVATIONAL","We intends to conduct a series of original clinical research about PA, and establish a large cohort of PA and essential hypertension patients with long-term follow-up of cardiovascular events, renal end points etc. We will establish a large sample of blood, urine, adrenal tissue of the subjects, and the genomics,metabonomics, proteomics database, to explore the mechanism of the PA and target organ damage, risk factors, diagnostic methods and biomarkers.",[72],"Primary Aldosteronism",[9,74,75],"cardiovascular events","cerebrovascular events","2023-09-04",{"date":78,"type":79},"2023-09-06","ACTUAL",{"date":81,"type":79},"2016-10-01",{"date":83,"type":68},"2028-12-31",{"name":5,"class":6},1]